Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 23andMe Holding Co. ME

Consumer Cyclical Healthcare Advertising Agencies
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including... see more

Recent & Breaking News (NDAQ:ME)

23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer's (SITC) 2022 Annual Meeting

GlobeNewswire October 5, 2022

Daniel Chu Joins 23andMe as Chief Product Officer

GlobeNewswire September 19, 2022

23andMe Reports FY2023 First Quarter Financial Results

GlobeNewswire August 8, 2022

23andMe to Report FY2023 First Quarter Financial Results

GlobeNewswire July 25, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Missfresh Limited - MF

PR Newswire July 21, 2022

23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results

GlobeNewswire May 26, 2022

Quarterhill Appoints John Karnes as CFO

PR Newswire May 24, 2022

23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results

GlobeNewswire May 12, 2022

23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

GlobeNewswire March 15, 2022

23andMe to Present at Cowen 42nd Annual Health Care Conference

GlobeNewswire February 25, 2022

23andMe to Present at Citi's 2022 Virtual Healthcare Conference

GlobeNewswire February 17, 2022

23andMe Reports FY2022 Third Quarter Financial Results

GlobeNewswire February 10, 2022

23andMe to Report FY2022 Third Quarter Financial Results

GlobeNewswire January 27, 2022

23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program

GlobeNewswire January 18, 2022

23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker

GlobeNewswire January 10, 2022

23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors

GlobeNewswire January 6, 2022

23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants

GlobeNewswire December 28, 2021

23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer

GlobeNewswire November 30, 2021

23andMe Announces Redemption of All Outstanding Warrants

GlobeNewswire November 22, 2021

23andMe Reports FY2022 Second Quarter Financial Results

GlobeNewswire November 10, 2021